NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
Zacks.com on MSN7h
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to BuyPLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ: ...
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.
Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce ...
Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
California, USA-based fibrosis specialist Pliant Therapeutics saw its shares leap 20.95% to $3.29 by close of trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback